Ribonucleotide reductase, a novel drug target for gonorrhea
- PTC Therapeutics, Inc., United States
- Bristol Myers Squibb, United States
- Schrödinger, Inc., United States
- PMV Pharmaceuticals, United States
- Massachusetts Institute of Technology, United States
- Howard Hughes Medical Institute, Massachusetts Institute of Technology, United States
- PTC Therapeutics Inc, United States
Peer review process
This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.
History
- Version of Record updated
- Version of Record updated
- Version of Record published
- Accepted Manuscript published
- Accepted
- Received
- Preprint posted
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Ribonucleotide reductase, a novel drug target for gonorrhea
eLife 11:e67447.
https://doi.org/10.7554/eLife.67447
